Clinical bottom line
Anti-IgLON5 disease is a rare, progressive neuroimmunological disorder characterized by a combination of sleep disturbances, cognitive decline, and motor symptoms that can mimic neurodegenerative or motor neuron diseases. Emerging evidence suggests that early recognition and initiation of immunotherapy may improve or stabilize cognitive and motor symptoms, although responses are variable and often incomplete. Clinicians should maintain a high index of suspicion for anti-IgLON5 disease in patients presenting with atypical neurodegenerative features combined with sleep disorders, as early intervention may alter disease trajectory (Thakolwiboon et al., 2024; Vijayaraghavan et al., 2026).
What the evidence shows
Anti-IgLON5 disease presents with a heterogeneous clinical spectrum including cognitive impairment, gait instability, bulbar dysfunction, and sleep-related breathing disorders. The pathophysiology involves autoantibodies targeting the neuronal cell adhesion protein IgLON5, leading to neurodegeneration with tauopathy features (Thakolwiboon et al., 2024).
Recent case reports and series highlight that early immunomodulatory treatment—primarily corticosteroids, intravenous immunoglobulin (IVIG), or plasma exchange—may improve symptoms or halt progression in some patients. Vijayaraghavan et al. (2026) describe a patient with a motor neuron disease-like phenotype who showed clinical stabilization following immunotherapy initiated after decades of sleep symptoms, underscoring the potential benefit of treatment even in late-stage presentations. Similarly, Thakolwiboon et al. (2024) emphasize the importance of comprehensive patient evaluation to identify early cognitive and motor signs amenable to immunotherapy.
Psychiatric symptoms, including anxiety and psychosis, are also reported and may respond variably to immunotherapy, as reviewed by Luo et al. (2023). However, the evidence base remains limited to observational studies and case reports, with no randomized controlled trials available to define optimal treatment protocols or timing.
Caveats and uncertainty
The rarity and clinical heterogeneity of anti-IgLON5 disease complicate diagnosis and management. Diagnostic delays are common due to symptom overlap with neurodegenerative diseases such as Parkinson’s disease or motor neuron disease, and the lack of widely available, standardized antibody testing (Hurley et al., 2026).
Immunotherapy responses are inconsistent; some patients experience stabilization or improvement, while others progress despite treatment (Thakolwiboon et al., 2024). The optimal immunotherapeutic regimen, duration, and timing remain undefined. Moreover, the underlying neurodegenerative tauopathy may limit reversibility of symptoms, particularly in advanced stages.
There is also limited data on long-term outcomes and the impact of early versus delayed intervention. Current evidence is primarily from small cohorts and case reports, which may be subject to publication bias and lack control groups.
How this may change practice
Neurologists should consider anti-IgLON5 disease in patients with unexplained combinations of sleep disorders, cognitive decline, and motor symptoms, especially when features are atypical for classical neurodegenerative syndromes. Early antibody testing and multidisciplinary evaluation including sleep studies and neuropsychological assessment are advisable (Thakolwiboon et al., 2024; Hurley et al., 2026).
Prompt initiation of immunotherapy may be warranted in suspected cases to potentially improve or stabilize symptoms, although clinicians should counsel patients regarding the variable and often incomplete response. Close monitoring for treatment efficacy and adverse effects is essential.
Increased awareness and earlier diagnosis may improve patient outcomes and guide future research into standardized treatment protocols. Collaborative registries and prospective studies are needed to better define the natural history and therapeutic windows in anti-IgLON5 disease.